Skip to content

NECANN horozontal white

EVENTS
TO EXHIBIT
SPEAKER APP
- PRESS PASS REQUEST
- NECC AWARDS
TESTIMONIALS
NECANN CUP
NEWS
CONTACT
ABOUT

Menu

EVENTS
TO EXHIBIT
SPEAKER APP
- PRESS PASS REQUEST
- NECC AWARDS
TESTIMONIALS
NECANN CUP
NEWS
CONTACT
ABOUT

Search

Search

Close this search box.

CANNABIS INDUSTRY NEWS

Cannabis News With NECANN

Pennsylvania Introduces Bipartisan Bill to Legalize Adult-Use Cannabis

Pennsylvania Introduces Bipartisan Bill to Legalize Adult-Use Cannabis

July 24, 2023

New Hampshire Allows Reciprocity for Medical Cannabis Patients

New Hampshire Allows Reciprocity for Medical Cannabis Patients

July 24, 2023

Minnesota Adds IBS and OCD to Medical Cannabis Program, Effective August 1

Minnesota Adds IBS and OCD to Medical Cannabis Program, Effective August 1

July 21, 2023

University of California, San Diego Receives $1.5 Million Gift to Study DMT Effects on the Brain

University of California, San Diego Receives $1.5 Million Gift to Study DMT Effects on the Brain

July 21, 2023

Maryland Sees Strong Cannabis Sales in First Week of Retail Rollout, with Medical Sales Leading the Way

Maryland Sees Strong Cannabis Sales in First Week of Retail Rollout, with Medical Sales Leading the Way

July 21, 2023

Florida Attorney General Challenges Cannabis Legalization Amendment in State Supreme Court

Florida Attorney General Challenges Cannabis Legalization Amendment in State Supreme Court

July 13, 2023

Licensed Hemp Farm in British Isles Forced to Shut Down as UK Government Declares Products Illegal

Licensed Hemp Farm in British Isles Forced to Shut Down as UK Government Declares Products Illegal

July 13, 2023

The U.S. Food and Drug Administration (FDA) has published its Draft Guidance for the research of psychedelic drugs, including psilocybin, LSD, and MDMA. This guidance outlines the regulatory requirements and unique challenges associated with studying the therapeutic potential of these substances. The FDA aims to ensure that clinical studies are designed appropriately to evaluate safety and effectiveness while considering the distinctive characteristics of psychedelic drugs. The FDA's Draft Guidance emphasizes that psychedelic drug development programs must adhere to the same regulations and evidentiary standards as other drug development programs. Compliance with the federal Food, Drug, and Cosmetics Act is essential, and non-clinical investigations should follow the guidelines outlined in the Nonclinical Safety Studies for Human Clinical Trials and Marketing Authorization for Pharmaceuticals. Designing clinical studies for psychedelic drugs presents unique challenges due to their profound effects on perception and consciousness, which can last for several hours. Some programs incorporate psychological or behavioral interventions, and researchers hypothesize that these drugs can provide rapid-onset and long-term benefits with just a few doses. These distinctive characteristics must be carefully considered to ensure the interpretability of study results. The FDA acknowledges that most medical conditions being studied in psychedelic research programs are chronic in nature. The proposed regulations provide a framework for psychedelic therapy, which is currently legal in Oregon. If the FDA were to approve a drug currently classified as a Schedule I substance under the Controlled Substances Act, the assessment of abuse potential would assist in determining appropriate rescheduling actions. The FDA is welcoming public comments on the proposed rules until August 28. This opportunity allows stakeholders and interested parties to provide feedback and contribute to the ongoing development of regulations for psychedelic drug research. Public input plays a crucial role in shaping the future of this field and ensuring safe and effective use of psychedelic therapies. Stay up-to-date with the ever-changing landscape of cannabis. Subscribe to NECANN today for the latest updates.

FDA Releases Draft Guidance for Psychedelic Drug Research

July 13, 2023

New York's Capital District Educational Opportunity Center to Launch Cannabis Construction Training Program

New York’s Capital District Educational Opportunity Center to Launch Cannabis Construction Training Program

July 13, 2023

Study Shows Teen Binge Drinking Declines with Cannabis Legalization, But Adults Show Increase

Study Shows Teen Binge Drinking Declines with Cannabis Legalization, But Adults Show Increase

July 13, 2023

Connecticut Allows Home Cannabis Cultivation for Adults

Connecticut Allows Home Cannabis Cultivation for Adults

July 13, 2023

Maryland Legalizes Cannabis Possession and Cultivation Now Allowed

Maryland Marijuana Legalization Law Takes Effect, Enabling Possession and Cultivation for Personal Use

July 13, 2023

Luxembourg Becomes Second EU Country to Legalize Cannabis Possession and Cultivation

Luxembourg Becomes Second EU Country to Legalize Cannabis Possession and Cultivation

July 13, 2023

Colombia Senate Narrowly Rejects Bill for Legal Cannabis Sales to Adults

Colombia Senate Narrowly Rejects Bill for Legal Cannabis Sales to Adults

July 2, 2023

Federal Ban Renews, Blocking D.C. Marijuana Sales

Federal Ban Renews, Blocking D.C. Marijuana Sales

July 2, 2023

Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Page21 Page22 Page23 Page24 Page25 Page26 Page27 Page28 Page29

Sort Posts By Category

Cannabis And Culture • Cannabis Business • Cannabis In Politics • Cannabis In Science & Health • Cannabis Legalization • NECANN News

SALES & SUPPORT

207-756-5948 | [email protected]

810-869-8031 | [email protected]

Support

207-400-4446 | [email protected]

508-561-6243 | [email protected]

HOME PAGE
CONVENTION SCHEDULE
EXHIBIT
CANNABIS NEWS
CONTACT
ABOUT

Twitter Facebook-f Instagram Youtube Linkedin

Copyright 2023 NECANN
All Rights Reserved. This publication is protected by US and international copyright laws. No part of this publication can be re-used or re-distributed except by our written permission.